Skip to main content
Equibles

MESO · Mesoblast Ltd · Metrics

Track MESO — free

Use MESO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MESO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.67 +2.28 (+17.03%) At close · Oct 29 Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$1.74B
Shares
129.85M
Volume · Oct 29 696.52K Avg daily vol (3M) 231.29K

MESO metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.67
Market cap
$1.74B

Price action

20 metrics
Price change (1W)
+4.4%
Price change (30D)
-10.0%
Price change (3M)
-5.2%
Price change (6M)
-13.9%
Price change (YTD)
-25.8%
Price change (1Y)
-20.0%
Trailing year
Price change (5Y)
—
52-week high
$20.96
52-week low
$11.95
Change from 52-week high
-36.1%
Change from 52-week low
+12.1%
Annualized volatility
54.7%
Annualized volatility (3M)
54.6%
Beta
1.5
RSI (14D)
46.7
Price vs SMA 50
-10.8%
Price vs SMA 200
-13.2%
Avg volume (3M)
224,443
Relative volume
0.8
Average dollar volume
$3.36M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
129.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
228.2×
reciprocal yield 0.4%
P / book
3.0
reciprocal yield 33.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-12-31

Profitability

9 metrics
Gross margin
86.1%
Operating margin
—
Trailing 12 months
Net margin
-1,091.7%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
−$81.89M
Trailing 12 months
Diluted EPS (TTM)
$-1.05
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$4.38

Growth

11 metrics
Revenue growth YoY
-13.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.50M
Trailing 12 months
EPS growth YoY
-26.1%
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
+152.1%
Revenue CAGR (5Y)
+74.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-16.3%
Return on assets
-12.2%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$102.91M
Total assets
$773.08M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$63.27M
Capital expenditures (TTM)
—
R&D (TTM)
$52.82M
SG&A (TTM)
—
Stock compensation (TTM)
$3.65M
R&D / revenue
704.1%
Stock compensation / revenue
48.7%

Ownership (13F)

9 metrics
13F filers
73
13F filer change QoQ
+4
Institutional ownership
4.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+20.2%
Holder tenure
12.2
Price vs estimated holder cost
-6.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 13.2 days to cover
Days to cover
13.2d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1345099 CUSIP 590717401 13F (30d) 12 filings 12 filers Visit website Investor relations